The US FDA's draft guidance on drug development in male hypogonadotropic hypogonadism does not apply to testosterone products such as Clarus Therapeutics Inc.' Jatenzo that are being developed as replacement therapies and using a well-established pathway.
The new draft guidance, released Jan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?